Vaccines and Global Health: The Week in Review
10 September 2022 :: Issue 670
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
::
Journal Watch
**Milestones, Perspectives**

---

**UNICEF Executive Director Catherine Russell’s opening statement at the second regular session of the UNICEF Executive Board**

NEW YORK, 6 September 2022

[Excerpt]

"...Our work also continues in earnest to address the tremendous secondary impact of the COVID-19 pandemic on children’s development, especially those who are already vulnerable.

"I would like to touch on two of the most serious threats to these children: disruptions in routine immunization, and the impact of the pandemic on learning.

"We know that health systems have been strained to the breaking point by the pandemic – especially those that were already weak. The impact on immunization rates has been swift and serious.

"Data published recently by WHO and UNICEF shows that in 2021 alone, 25 million children did not receive the basic vaccine against diphtheria, tetanus, and pertussis – a marker for immunization coverage in general.

"This is the largest sustained drop in the rates of routine childhood vaccinations in a generation – potentially wiping out 30 years of progress, if we don’t get back on track.

"The cost of inaction will be measured in children’s lives. We have already seen outbreaks of measles and other vaccine preventable diseases in an increasing number of countries over the last two years.

"We need urgent action to reach the ‘missing millions.’ UNICEF is calling on all Member States with high numbers of children who have missed immunization to invest in dedicated catch-up campaigns now. We do not have a moment to lose...”

---

**Malaria**

**WHO grants prequalification to GSK’s Mosquirix – the first and only approved malaria vaccine**

- First prequalification for a malaria vaccine
- Important step for rolling out the vaccine to children living in regions with moderate to high transmission

06 September 2022

GSK plc (LSE/NYSE: GSK) announced today that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK’s groundbreaking malaria vaccine. This is the first prequalification for a malaria vaccine and is an important step in rolling out the vaccine in countries with moderate to high P. falciparum malaria transmission.
The WHO prequalification decision is a mandatory prerequisite for United Nations (UN) agencies, such as UNICEF, to procure the vaccine in partnership with Gavi, the Vaccine Alliance, and eligible countries. Pre-qualification for Mosquirix is the result of a rigorous regulatory process with the assessment of clinical, safety and technical data ensuring that the vaccine meets standards of quality, safety and efficacy, and is suitable for the target population.

**Thomas Breuer, Chief Global Health Officer, GSK, said:** “WHO prequalification of Mosquirix is a key step in reaching children with the first and only approved malaria vaccine. Malaria remains a significant cause of illness and death for children in many parts of the world, and it is a significant driver of inequality. So far, over 1 million children in Ghana, Kenya and Malawi have had at least one dose of Mosquirix, donated by GSK, through the Malaria Vaccine Implementation Programme, and WHO’s prequalification paves the way for more children to benefit from the vaccine.”

**About Mosquirix**
Working in collaboration with PATH and other partners, GSK developed Mosquirix, the first vaccine to help protect children against the deadliest form of malaria, P. falciparum. In 2021, WHO recommended broader use of GSK’s Mosquirix to reduce childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission as defined by WHO. GSK is currently working with partners to accelerate a product transfer for long-term antigen production, including technology transfer, to Bharat Biotech of India. This partnership is expected to enable more efficient production at higher volumes over time.

---

**Pandemic Response – Financial Intermediary Fund [FIF]**

**New fund for pandemic prevention, preparedness and response formally established**
Designed to reflect inclusive and effective governance and operating arrangements with high standards of transparency and accountability; hosted by the World Bank with technical leadership from WHO
9 September 2022 Joint News Release
Washington D.C.

The new financial intermediary fund (FIF) for pandemic prevention, preparedness, and response (PPR) was officially established by the FIF Governing Board at its inaugural meeting from 8-9 September 2022.

The fund will provide a dedicated stream of additional, long-term financing to strengthen PPR capabilities in low- and middle-income countries and address critical gaps through investments and technical support at the national, regional, and global levels. The fund will draw on the strengths and comparative advantages of key institutions engaged in PPR, provide complementary support, improve coordination among partners, incentivize increased country investments, serve as a platform for advocacy, and help focus and sustain much-needed, high-level attention on strengthening health systems.

The first calls for proposals for investments to be funded by the FIF will open in November 2022.
“COVID-19 has highlighted the pressing need for action to build stronger health systems,” said World Bank Group President David Malpass. “Investing now will save lives and resources for the years to come. We welcome the broad support from the international community for this new, multilateral financial intermediary fund at the World Bank to help low- and middle-income countries and regions become better prepared for global health crises and are pleased to have been able to proceed quickly in establishing the fund.”

The fund’s establishment follows approval by the World Bank’s Board of Directors on June 30, 2022. The World Bank will serve as the FIF’s trustee and host the Secretariat, which will include technical staff seconded from the World Health Organization (WHO). The Governing Board will appoint a Technical Advisory Panel, chaired by WHO, and comprising leading experts to assess and make recommendations to the Governing Board on the technical merits of proposals for funding, ensuring linkages to the International Health Regulations, as part of the broader global PPR architecture.

“The COVID-19 pandemic has been a seismic shock to the world, but we also know that the next pandemic is a matter of when, not if,” said WHO Director-General, Dr Tedros Adhanom Ghebreyesus. “The suffering and loss we have all endured will be in vain unless we learn the painful lessons from COVID-19 and put in place the measures to fill critical gaps in the world’s defences against epidemics and pandemics. The FIF is one of those key measures, and WHO looks forward to fulfilling its technical leadership role in advising the FIF Board on where to make the most effective investments to protect health, especially in low- and middle-income countries.”

The new fund is overseen by a Governing Board, which will set the overall work program and make funding decisions. The FIF’s Governing Board includes equal representation of sovereign donors and potential implementing country governments (co-investors), as well as representatives from foundations and civil society organizations (CSOs).

The World Bank and WHO will intensify their work with the Governing Board in consultation with CSOs and other stakeholders, to help operationalize the fund and develop the FIF results framework and priorities in the run up to the first call for proposals.

FIF financing could help strengthen and sustain PPR capacity in areas such as zoonotic disease surveillance; laboratories; emergency communication, coordination and management; critical health workforce capacities; and community engagement. FIF-financed projects can also help strengthen PPR at the regional and global levels, for example, by building capacity for medical countermeasures. The FIF can support peer-to-peer learning, provide targeted technical assistance, and help with the systematic monitoring of PPR capacities.

The FIF was developed with broad support from members of the G20 and beyond. Over US$1.4 billion in financial commitments have already been announced and more are expected in the coming months.

So far, commitments have been made by Australia, Canada, China, the European Commission, France, Germany, India, Indonesia, Italy, Japan, Republic of Korea, New Zealand, Norway, Singapore, South Africa, Spain, the United Arab Emirates, the United Kingdom, the United States, the Bill & Melinda Gates Foundation, the Rockefeller Foundation, and Wellcome Trust.
WHO Director-General’s opening remarks at the Inaugural meeting of the Governing Board of the Financial Intermediary Fund for Pandemic Prevention, Preparedness and Response – 8 September 2022

Speech
[Excerpt]

...At the request of our Member States, in May this year WHO published a white paper with 10 key proposals for strengthening the global architecture for health emergency preparedness, response and resilience.

Importantly, our Member States have affirmed that the International Health Regulations must remain the foundation of that architecture, supplemented by a new international accord, which as you know is now being negotiated.

A recurring theme of the reviews, and one of the 10 key proposals in our White Paper, is to create a new Financial Intermediary Fund to provide catalytic and gap-filling funding for Pandemic Prevention, Preparedness and Response.

The vital role of the FIF will be to rapidly close critical gaps globally, regionally and nationally, in core capacities for implementing the International Health Regulations, with a risk-based approach, and with countries in the driver’s seat.

This will require careful analysis and prioritization, which will be the hardest job for the Board and the Technical Advisory Panel.

As the custodian of the IHR, WHO looks forward to playing its central coordinating role as Chair of the Technical Advisory Panel, and in providing technical leadership and guidance to the board.

Thank you all once again for everything you have done to bring us to this point.

The task before is urgent, so I challenge you to work with the urgency this work demands, to finalize the founding documents, so we can focus on other immediate priorities and issue the first call for proposals before the G20 leaders meet in November.

WHO is totally committed to playing our part to make the FIF a success, and to build a healthier, safer, fairer future for all the people of the world...

Nature Medicine
Comment
Published: 08 September 2022

Wastewater surveillance of pathogens can inform public health responses
Megan B. Diamond, Aparna Keshaviah, Samuel V. Scarpino, et al.
Wastewater monitoring has been used to identify SARS-CoV-2 outbreaks and track new variants. This sentinel system should be expanded to monitor other pathogens and boost public health preparedness.

Fig. 1: Wastewater-monitoring pathway.

From: Wastewater surveillance of pathogens can inform public health responses

After SARS-CoV-2 is shed in human feces, the sewage may travel to centralized locations, such as wastewater treatment plants. Depending on the goals and resources for wastewater monitoring, a variety of methods can be used to collect samples of the sewage, which is routinely done between twice weekly and once monthly. The samples are first processed in a lab to concentrate and amplify genetic evidence (RNA or DNA, depending on the pathogen). Genetic material is then tested to detect and quantify pathogens of interest, with PCR-based methods or NGS used for variant detection. Results are then reported to public health departments to improve situational awareness and inform action.

Leading U.S. Scientists and Researchers, Backed by The Rockefeller Foundation’s Pandemic Prevention Institute, Issue Urgent Call To Scale Up Wastewater Monitoring

Press Releases

NEW YORK | September 8, 2022 — In a commentary published today in Nature Medicine, a group of public health leaders and academic researchers brought together by The Rockefeller Foundation’s Pandemic Prevention Institute outlines the urgent need to increase investments in wastewater surveillance to detect and contain health threats, such as monkeypox. As the authors demonstrate through three case studies on wastewater monitoring for Covid-19 variants, this type of surveillance can provide a powerful early warning system for outbreaks, but it is currently too limited in scope and
is not yet fully integrated into public health systems – which severely impedes pandemic preparedness and response efforts.

“The science underpinning wastewater surveillance for disease outbreaks is settled – what’s missing is widespread and consistent implementation by public health authorities,” said Samuel V. Scarpino, PhD, co-author of the Nature Medicine paper and Vice President of Pathogen Surveillance at The Rockefeller Foundation’s Pandemic Prevention Institute. “Additionally, it is high time that we expand wastewater surveillance so that we are proactively scanning for a wider range of viral and bacterial threats. In the race against disease outbreaks, the speed of our response is key – and scaled-up wastewater monitoring could significantly accelerate detection and the subsequent global response.”...

To overcome these challenges, the authors present three key recommendations, which serve as a roadmap for fully operationalizing wastewater surveillance:

▪ **Greater funding and investment** to support the required infrastructure, including wastewater-sampling equipment, lab testing supplies and trained personnel;
▪ **Researcher expertise** for deriving new assays, developing risk metrics, and communicating outbreak risk to non-technical audiences; and
▪ **Community engagement**, because the value of wastewater data is optimized when multiple stakeholders work closely together, and community leaders are engaged and consulted on the wastewater sampling process...

---

**Report Calls for Structural Public Health Changes to Increase Vaccine Demand and Stop Future Disease Outbreaks**

*Press Releases*

Sep 06 2022

*New report, from researchers at Brown University calls for investment in community leadership; provides key strategies for public health officials, institutions, and policy makers.*

PROVIDENCE, R.I. | September 6, 2022 – As the United States has begun the rollout of second generation updated Covid-19 vaccines, a new report from researchers at the Brown University School of Public Health with support from The Rockefeller Foundation finds that **despite dramatically expanded capacities to develop, manufacture, and deliver effective vaccines, it will be people’s confidence in and widespread access to vaccines that will decide whether this critical public health solution will be successful.** With one third of Americans having gotten only one Covid shot or none, the report calls for a significant investment in vaccine demand generation to address the rampant disinformation, the erosion of trust in public health, and the lack of access to health services that has undermined the United States’ vaccination efforts to date.

Calling it an ‘all-of-society’ challenge, the new report examines how “if we build it, they will come” strategies can backfire, and how a better understanding of a significantly changed media environment and structural barriers to vaccine uptake impact decision making can improve vaccination efforts. The report delivers a new framework to guide vaccine demand generation strategies overall and calls for investment in people and programs, adjustments in policies and regulations,
and a commitment to building new infrastructures to increase trust, health equity, and meet the information needs of diverse communities.

“Under-vaccination remains a key reason why we haven’t emerged more resilient one-and-a-half years after vaccines became widely available,” said Stefanie Friedhoff, co-director of the Information Futures Lab at Brown University and the lead author of the report. “It is easy to blame people for making bad choices but if we do not understand the underlying reasons for why so many aren’t accessing these lifesaving measures, we risk staying stuck in the same cycle.”

The report provides a set of policy recommendations for public health officials, institutions, and policymakers to build and maintain a stronger public health system that protects Americans from a lingering pandemic – and future ones. The recommendations include:

- **Invest in a communications infrastructure** – similar to other aspects of pandemic preparedness – that builds trust in public health guidance over time and makes public health communications everyone’s job. This includes building in flexibility to address evolving information needs and to fight disinformation tactics that sow fear and doubt in vaccinations.

- **Be in solidarity with community by aligning with their priorities, needs, and values** to make it easier for individuals to see how the vaccine fits into their life and frame vaccination as a decision that makes sense. This is an essential component that builds trust, integrates interventions into other needed services, and creates a more equitable public health system.

- **Integrate vaccine demand assessments and strategic planning into pandemic preparedness and resilience efforts at all levels of government, industry, and the nonprofit sector** – from the start...

---

**PHEIC**

**Monkeypox**

**Multi-country outbreak of monkeypox, External situation report #5 - 7 September 2022**

Highlights

:: During the week of 29 August to 4 September 2022, the number of cases reported in the regions of Europe and America declined compared to the week of 22 to 28 August, driving the observed global decrease.

:: On 25 August, WHO updated the interim guidance on surveillance, case investigation, and contact tracing for monkeypox with the latest information on symptomatology and epidemiological parameters, and to align with the Temporary Recommendations issued by the Director General, after the

:: On 1 September, WHO published new public health advice on preventing stigma and discrimination: Communications and community engagement interim guidance on using inclusive language in understanding, preventing and addressing stigma and discrimination related to monkeypox.

---

**PHEIC**
Weekly Epidemiological and Operational updates

Last update: 31 Aug 2022

**Confirmed cases**: 603 711 760
**Confirmed deaths**: 6 484 136
**Vaccine doses administered**: 12 478 615 692

---

Weekly epidemiological update on COVID-19 - 7 September 2022

**Overview**

Globally, the number of weekly cases decreased by 12% during the week of 29 August to 4 September 2022 as compared to the previous week, with just under 4.2 million new cases reported. The number of new weekly deaths decreased by 5% as compared to the previous week, with over 13 700 fatalities reported. As of 4 September 2022, over 600 million confirmed cases and over 6.4 million deaths have been reported globally.

---

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 010 Sep 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

- 40 vaccines approved for use by at least one national regulatory authority
- 11 vaccines in WHO’s Emergency Use Listing
- 1.72bn doses shipped through COVAX to 146 countries
- 18.0bn doses secured globally
- $2 - $40 reported vaccine price range per dose
- 21K novel oral antiviral therapeutic treatments arrived in 1 countries

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 010 Sep 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution
[accessed 24 July 2021]
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
010 Sep 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 119M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 12.6B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 350M
Other Delivered (Number of Doses): 390M
Total Delivered (Number of Doses): 740M
Total Administered (Number of Doses): 490M
**Global COVID-19 Access Tracker**
[https://www.covid19globaltracker.org/](https://www.covid19globaltracker.org/)

The ACT-Accelerator and Multilateral Leaders Task Force Global COVID-19 Access Tracker (GCAT) is a dynamic tool to transparently track progress towards the global targets for access to COVID-19 vaccines, treatments, tests and PPE.

- **Vaccination**: 80 countries with vaccination coverage >70%
- **Testing**: 24 countries testing daily at rate >10/100K pop
- **Therapeutics**: --- all cases cared for in all countries (unavailable)
- **Health Workers**: --- all healthcare workers protected (unavailable)

- **1.7 Bn** doses delivered by COVAX to date
- **951 Mn** tests delivered via ACT-A to date
- **US$ 230 Mn** treatments & O2 supplies delivered via ACT-A to date
- **US$ 565 Mn** Personal Protective Equipment (PPE) delivered via ACT-A to date

Website accessed 010 Sep 2022: [https://data.covid19taskforce.com/data](https://data.covid19taskforce.com/data) The global view below is complemented by country-specific dashboards here.

**Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**
[https://data.covid19taskforce.com/data](https://data.covid19taskforce.com/data)

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 010 Sep 2022: [https://data.covid19taskforce.com/data](https://data.covid19taskforce.com/data) The global view below is complemented by country-specific dashboards here.
Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 010 Sep 2022]

:: 67.8% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.63 billion doses have been administered globally, and 4.23 million are now administered each day.
:: Only 21% of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

Statement from HHS Secretary Xavier Becerra on CDC’s Recommendation of An Updated COVID-19 Vaccine
September 7, 2022 | News Release

HHS Secretary Becerra Issues 564 Declaration to Expand the Availability of Testing for Monkeypox
September 7, 2022 | News Release

HHS Awards $20 Million Contract to AmerisourceBergen to Expand, Quicken Distribution of Vaccines and Treatments for Monkeypox
September 6, 2022 | News Release

FDA
European Medicines Agency

News & Press Releases

News: ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines (new)
Last updated: 06/09/2022

The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have issued a joint statement providing updated public health considerations on the use of the newly authorised adapted COVID-19 vaccines to support the planning of the autumn and winter vaccination campaigns.

The EU has recently extended its arsenal with two new updated vaccines, Comirnaty Original/Omicron BA.1 and Spikevax Bivalent Original/Omicron BA.1. As the virus SARS-CoV-2 continues to evolve, the existing vaccines are being adapted to ensure optimal protection of EU citizens against COVID-19.

The two bivalent formulations for use as a booster dose recently recommended for approval by EMA expand the immunity versus variants of concern, especially Omicron and related sub lineages. Exposing the immune system to contemporary versions of the virus so that it learns and recognizes subsequent variants is key for building up a broader immune response...

------

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en

Latest Updates [Selected]

Publication
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA
Guidance - 8 Sep 2022

Publication
Monkeypox (MPX) Reporting Protocol 2022
Guidance - 8 Sep 2022

News
Weekly COVID-19 country overview
Epidemiological update - 8 Sep 2022

News
Joint ECDC-WHO/Europe monkeypox surveillance bulletin
Epidemiological update - 7 Sep 2022
News

**Monkeypox situation update, as of 6 September 2022**
Epidemiological update - 7 Sep 2022

---

**European Commission**
https://ec.europa.eu/commission/presscorner/home/en

Latest [Selected]

**Press release 7 September 2022**

**Health Union: HERA secures additional vaccine doses in the fight against the monkeypox outbreak**

Today, HERA, the Commission's Health Emergency Preparedness and Response Authority, has secured an additional 170,920 doses of Bavarian Nordic's 3rd generation vaccine to respond to the ongoing monkeypox outbreak and to meet the more immediate needs.

---

**Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**
https://africacdc.org/covid-19-vaccination/

**Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**Russia: Sputnik V – "the first registered COVID-19 vaccine”**
https://sputnikvaccine.com/newsroom/pressreleases/

Press Releases
No new digest content identified.
India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on: 10 September 2022, 08:00 IST (GMT+5:30)
(↑↓ Status change since yesterday)

- Active: 48,850 (0.11%)
- Discharged: 43,913,294 (98.70%)
- Deaths: 528,139 (1.19%)

COVID-19 Vaccination as on: 10 September 2022, 08:00 IST (GMT+5:30)

Total Vaccination: 2,147,755,021 (21,63,811 ↑)

Government of India – Press Information Bureau
Latest Press Releases

COVID - 19 Vaccination Update - Day 603
- India’s cumulative vaccination coverage crosses 214.92 Crore
- More than 14 lakh Vaccine doses administered today till 7 pm
Posted On: 10 SEP 2022 8:26PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations...]

PHEIC
Polio
Polio this week as of 07 Sep 2022 - GPEI
:: The 22nd meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC) took place in Geneva on 28 and 29 June 2022, chaired by Professor David Salisbury. The objective of the meeting was to review progress toward eradication of WPV, including the response to the outbreak of WPV1 in southern Africa and to review progress toward stopping and preventing outbreaks of cVDPV2 among others. The meeting report is now available here.

:: Following the isolation of vaccine-derived poliovirus type 2 (VDPV2) from environmental samples in London, UK, in May 2022, further virological and epidemiological analysis confirms circulation of this strain. No cases of paralysis associated with this strain have been detected – virus has been isolated only from environmental (sewage) samples. It is important to note that since initial isolation of VDPV2 in May, local and national public health authorities have already been operating on the assumption that this strain is circulating, and as such, this official classification at this time does not affect the operational response. London and UK public health authorities continue to implement a timely and appropriate response to this circulating VDPV2 (cVDPV2), in order to rapidly interrupt its circulation, including by: continuing to intensify surveillance efforts (including for potential cases of paralysis), identifying population sub-groups/areas with potential immunity gaps, offering an additional dose of inactivated polio vaccine (IPV) to all children (aged 1-9 years of age) across London, and proactively reaching out to communities with known immunity gaps to strengthen vaccination coverage.

Summary of new polioviruses this week:
– Pakistan: two WPV1 cases
– Mozambique: two cVDPV1 cases
– DR Congo: seven cVDPV2 cases and one positive environmental sample
– Ghana: one cVDPV2 case and one positive environmental sample
– Niger: two cVDPV2 positive environmental samples
– United Kingdom: two cVDPV2 positive environmental samples
– Yemen: 10 cVDPV2 cases

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
No new digest content identified.

Northern Ethiopia
No new digest content identified.

Somalia
No new digest content identified.

Ukraine
Ukraine: Situation Report - Last updated: 07 Sep 2022
WHO & Regional Offices [to 010 Sep 2022]
https://www.who.int/news
Selected News/Announcements/Statements
9 September 2022
Joint News Release
New fund for pandemic prevention, preparedness and response formally established

7 September 2022
Departmental news
Training course on One Health in action against Neglected Tropical Diseases

6 September 2022
Departmental news
WHO releases new module of the PrEP implementation tool on integration of STI services

5 September 2022
Departmental news
WHO and partners launch a new online resource to advance STI vaccine development

WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches
Selected Speeches
8 September 2022
Speech
WHO Director-General's opening remarks at the Inaugural meeting of the Governing Board of the Financial Intermediary Fund for Pandemic Prevention, Preparedness and Response – 8 September 2022

7 September 2022
Speech
WHO Director-General's opening remarks at the media briefing– 7 September 2022

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
:: COVID-19 threatens elimination of deadly form of meningitis in Africa, more than 50 million children miss vaccination 08 September 2022

WHO Region of the Americas PAHO
:: 7 Sep 2022
With the Americas facing COVID-19 and monkeypox, prevention is key to tackling outbreaks and protecting public health, PAHO Director says

Washington D.C. 7 September 2022 (PAHO) – With the Americas now accounting for highest numbers of monkeypox cases in the world, and COVID-19 remaining a “significant threat” to the region, prevention is key to avoiding infection and protecting peoples’ health, the Pan American Health Organization (PAHO) Director, Dr. Carissa F. Etienne said....

:: 3 Sep 2022

Update – Legionella identified as cause of cluster of pneumonia cases in Tucuman, Argentina

WHO South-East Asia Region SEARO
:: 9 September 2022   News release
WHO South-East Asia Region commits to inclusive, equitable and resilient health systems
:: 8 September 2022   News release
WHO South-East Asia Region roadmap to strengthen emergency preparedness and response
:: 7 September 2022   News release
WHO South-East Asia Region to accelerate progress for NCD prevention and control

WHO European Region EURO
:: 72nd session of the WHO Regional Committee for Europe
Tel Aviv, Israel, 12-14 September 2022
:: 10 September 2022   News release
Countdown to the annual meeting of ministers setting the health agenda across the European Region
:: 8 September 2022   News release
HPV self-sampling in Sweden leading to faster elimination of cervical cancer
:: 7 September 2022   News release
Uzbekistan achieves high HPV vaccination coverage against cervical cancer

WHO Western Pacific Region
No new digest content identified.

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

5 September 2022   |   Legionellosis - Argentina

WHO Events
https://www.who.int/news-room/events/1
[Selected]
Immunization and vaccines related implementation research advisory committee (IVIR-AC) - September 2022
12 – 16 September 2022

::: New WHO Publications
https://www.who.int/publications/i

Selected Titles
7 September 2022
Monitoring progress on universal health coverage and the health-related Sustainable Development Goals...

6 September 2022
Regulations and Laws promoting health and well-being goals (SDG3) in WHO South-East Asian countries

6 September 2022
Framework and toolkit for infection prevention and control in outbreak preparedness, readiness and response...

5 September 2022
WHO Expert Committee on Biological Standardization. Seventy-fifth report

4 September 2022
Imagining the future of pandemics and epidemics: a 2022 perspective

Global report
Overview
The World Health Organization's 1st foresight report - “Imagining the Future of Pandemics and Epidemics”, attempts to explore what the future of infectious threats might look like, using a short time horizon (3-5 years) to encourage immediate action. Inspired by the COVID-19 pandemic, the report sets out possible scenarios which are not predictions of the future, but instead invite us to imagine the different directions that the current and future pandemics might take and to expand the range of plausible futures. The scenarios are an opportunity to identify possible risks and solutions, discuss implications and propose actions aimed at preventing the occurrence or mitigating the impact of the current and future infectious threats.

CDC/ACIP [U.S.] [to 010 Sep 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases
No new digest content identified.

ACIP Meetings
Next ACIP Meeting
MMWR Weekly: Current Volume (71)
September 9, 2022 / No. 36
PDF of this issue
- Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder — Chongqing, China, 2022
- Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2 Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens — San Francisco Bay Area, California, July 2021—March 2022
- Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or Without Known Epidemiologic Link to Monkeypox — United States, 2022

Coronavirus Disease 2019 (COVID-19)-CDC
Approximately 15 announcements/reports/data summaries.

Africa CDC [to 010 Sep 2022]
http://www.africacdc.org/
News
Africa CDC and Partners mobilize National EPI Managers and other Stakeholders to accelerate COVID-19 vaccination in Africa.
ADDIS ABABA ETHIOPIA, 05 September 2022 – The Africa Centres for Disease Control and Prevention (Africa CDC) in collaboration with UNICEF, WHO and other key stakeholders, through the Saving Lives and Livelihoods programme in partnership with the Mastercard Foundation, is hosting a continental workshop for managers in the Expanded Programme on Immunization (EPI), to track progress towards achieving the 70 per cent vaccination target by the end of 2022, while reaching most vulnerable groups and strengthening countries’ health systems and routine immunization...

China CDC
http://www.chinacdc.cn/en/
National Health Commission of the People's Republic of China [to 010 Sep 2022]
http://en.nhc.gov.cn/
News
Sept 10: Daily briefing on novel coronavirus cases in China
On Sept 9, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 290 new cases of confirmed infections.

National Medical Products Administration – PRC  [to 010 Sep 2022]
http://english.nmpa.gov.cn/

News

Chinese mainland reports 259 new local confirmed COVID-19 cases
2022-09-09
The Chinese mainland on Thursday reported 259 locally transmitted confirmed COVID-19 cases, including 59 in Sichuan and 42 in Inner Mongolia, according to the National Health Commission's report Friday.

CCDC Weekly Reports: Current Volume (4)
2022-09-09 / No. 36   HEALTHY CHINA ISSUE
View PDF of this issue
- Healthy China: Proactive Health: An Imperative to Achieve the Goal of Healthy China
- Healthy China: China’s Actions to Achieve Universal Health Coverage for Children
- Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, June 2022

:::::::
:::::::
:::::::

Organization Announcements

Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group  [to 010 Sep 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation  [to 010 Sep 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 010 Sep 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of
mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people.

News: Articles and Publications
No new digest content identified.

**CARB-X [to 010 Sep 2022]**
https://carb-x.org/
News
No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 010 Sep 2022]**
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of *Vaccines and Global Health: The Week in Review* are available here.
:: *Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022* is now posted here.

**CEPI – Coalition for Epidemic Preparedness Innovations [to 010 Sep 2022]**
http://cepi.net/
Latest News
*The Race to Future-Proof Coronavirus Vaccines*
   To help humanity get ahead, we need vaccines that provide broad protection against new variants of COVID-19 as well as future coronavirus threats.
08 Sep 2022

**DARPA – Defense Advanced Research Projects Agency [U.S.] [to 010 Sep 2022]**
https://www.darpa.mil/news
News
No new digest content identified.

**Duke Global Health Innovation Center [to 010 Sep 2022]**
https://dukeghic.org/
Our Blog
No new digest content identified.

**EDCTP [to 010 Sep 2022]**
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.
No new digest content identified.

**Emory Vaccine Center**  [to 010 Sep 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

**European Vaccine Initiative**  [to 010 Sep 2022]
http://www.eu vaccine.eu/
Latest News, Events
**Blood-stage malaria vaccine candidate BK-SE36 shown to be safe and immunogenic in children**
05 September 2022

**Evidence Aid**  [to 010 Sep 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Selected Resources
**Effects of lockdown measures (search up to January 2021)**
**Added September 5, 2022**

**Fondation Merieux**  [to 010 Sep 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

**Gavi**  [to 010 Sep 2022]
https://www.gavi.org/
News Releases
9 September 2022
**Gavi Vaccine Investment Strategy Steering Committee is now open for applications**
5 September 2022
**Call for Applications: COVAX seeks experts for independent group on evidence-based vaccine decision-making**

**GHIT Fund**  [to 010 Sep 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified
Global Fund to Fight AIDS, TB and Malaria Grateful for Her Majesty Queen Elizabeth II’s Contributions to Health and Well-being

The Global Fund to Fight AIDS, TB and Malaria is saddened by the death of Her Majesty Queen Elizabeth II and grateful for her contributions over the years to improve health and well-being around the world. During her reign, the United Kingdom has been...  
08 September 2022

Global Fund Commends Germany’s Outstanding Leadership in Global Health

The Global Fund to Fight AIDS, Tuberculosis and Malaria praises Germany for its extraordinary leadership in global health with an early pledge announcement of €1.3 billion to help the world get back on track to end the three diseases by 2030, reduce ...  
08 September 2022

The Children’s Investment Fund Foundation (CIFF) Commits US$33 Million to Break the Cycle of HIV Transmission

The Global Fund to Fight AIDS, Tuberculosis and Malaria welcomes the Children’s Investment Fund Foundation (CIFF) pledge of US$33 million to accelerate progress in the fight against HIV transmission in up to five priority countries. The Global Fund i...  
08 September 2022

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]

No new digest content identified

Hilleman Laboratories

No new digest content identified

HHMI - Howard Hughes Medical Institute

No new digest content identified.

Human Vaccines Project

No new digest content identified.
IAVI [to 010 Sep 2022]
https://www.iavi.org/
Latest News
FEATURES
September 1, 2022
**IAVI launches toolkit to build vaccine literacy knowledge**
Covering HIV, TB, and Lassa virus vaccines, from basic science and clinical trials to social and ethical issues related to vaccine development and testing, as well as future access.

ICRC [to 010 Sep 2022]
What’s New [Selected]
**ICRC: "The humanitarian imperative is clear: children need to be in schools, even during armed conflict"**
Statement from ICRC President Peter Maurer on the need to protect education from attack during armed conflict and violence.
08-09-2022 | Statement

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 010 Sep 2022]
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 010 Sep 2022]
Press Documents
No new digest content identified.

IOM / International Organization for Migration [to 010 Sep 2022]
News
No new digest content identified.

ISC / International Science Council  [to 010 Sep 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
News
No new digest content identified.

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC  [to 010 Sep 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI  [to 010 Sep 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security  [to 010 Sep 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News [Selected]
No new digest content identified.

MSF/Médecins Sans Frontières  [to 010 Sep 2022]
http://www.msf.org/
Latest [Selected Announcements]
HIV/AIDS
Countries must re-engage on HIV, TB and malaria or risk seeing everything undone
Project Update 7 Sep 2022

National Academy of Medicine - USA  [to 010 Sep 2022]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 010 Sep 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 010 Sep 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
September 22-23, 2022 NVAC Meeting

NIH [to 10 Sep 2022]
http://www.nih.gov/
News Releases
U.S. clinical trial evaluating antiviral for monkeypox begins
September 9, 2022 — NIH trial to gather data on tecovirimat (TPOXX).

NIH seeks the next generation of COVID-19 diagnostics
September 8, 2022 — Funded through the RADx Tech program, new tests should feature improved accessibility and performance.

NIH researchers develop gene therapy for rare ciliopathy
September 8, 2022 — Gene augmentation rescues cilia defects in light-sensing cells derived from patients with blinding disease.

Clinical Trial Evaluating Monkeypox Vaccine Begins
September 8, 2022 — NIH Trial is Evaluating Intradermal Delivery to Expand the Vaccine Supply.

PATH [to 010 Sep 2022]
https://www.path.org/media-center/
Press Releases
Serving Life project transitions innovative HIV service delivery models to Ukrainian government for institutionalization and scale-up
The PATH-led USAID/PEPFAR Serving Life project introduced, scaled, and successfully transitioned an integrated, person-centered package of comprehensive health services in prison and community settings to enhance the delivery of testing and treatment services among key populations in Ukraine.
Published: September 2022
Type: Press Release

PATH applauds the establishment of new fund for pandemic prevention, preparedness, and response
Published: September 2022
PATH’s Chief Scientific Officer accepts role with FDA agency, CBER
Published: September 2022
Type: Announcement

**P. vivax malaria elimination efforts boosted by new agreement to expand access to G6PD testing**
September 8, 2022: MedAccess, PATH, and SD Biosensor today announced a new partnership aimed at advancing progress towards elimination of P. vivax malaria. The partnership will increase access to G6PD testing, which provides doctors with essential information to prescribe the safest, most effective course of treatment for P. vivax malaria patients.
Published: September 2022
Type: Press Release

**PATH welcomes WHO prequalification of the first malaria vaccine**
The vaccine's prequalification is a key step in protecting children and reducing the burden of malaria.

**Rockefeller Foundation** [to 010 Sep 2022]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Sep 08 2022
Press Releases
**Leading U.S. Scientists and Researchers, Backed by The Rockefeller Foundation’s Pandemic Prevention Institute, Issue Urgent Call To Scale Up Wastewater Monitoring**
NEW YORK | September 8, 2022 — In a commentary published today in Nature Medicine, a group of public health leaders and academic researchers brought together by The Rockefeller Foundation’s ...

Sep 06 2022
Press Releases
**Report Calls for Structural Public Health Changes to Increase Vaccine Demand and Stop Future Disease Outbreaks**
New report, Infrastructures of Trust: The Case for Investing in Vaccine Demand from researchers at Brown University calls for investment in community leadership; provides key strategies for public health officials, ...

**Sabin Vaccine Institute** [to 010 Sep 2022]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

**UNAIDS** [to 010 Sep 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
7 September 2022
People living with HIV speak loudly and clearly at World Council of Churches Assembly

7 September 2022

UNAIDS launches new platform on ending HIV-related stigma and discrimination in the Asia and Pacific region

UNHCR Office of the United Nations High Commissioner for Refugees [to 010 Sep 2022]
News Releases
No new digest content identified.

UNICEF [to 010 Sep 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Remarks
06 September 2022
UNICEF Executive Director Catherine Russell’s opening statement at the second regular session of the UNICEF Executive Board

NEW YORK, 6 September 2022 – "Excellencies, distinguished delegates, colleagues, "Good morning. I am very glad to be here and look forward to our work together this week. "I want to begin by congratulating Ambassador Maritza Chan Valverde, who has assumed the role of President of the UNICEF Executive Board. I am delighted to welcome you here today...

Press release
04 September 2022
UNICEF delivers life-saving supplies to help children affected by floods in Pakistan

ISLAMABAD, 4 September 2022 – UNICEF today delivered 32 metric tons of life-saving medical and other emergency supplies to support children and women affected by devastating floods across Pakistan. The shipment arrived in Karachi from UNICEF’s Supply

Unitaid [to 010 Sep 2022]
https://unitaid.org/
Featured News
06 September 2022
Unitaid launches major new investment to increase tuberculosis detection and find the missing millions
- New US$30 million investment will improve access to same-day test results to enable more people to quickly access appropriate treatment.
- Two complementary programs will accelerate the introduction of new diagnostic technologies, evaluate alternative sampling approaches, and develop optimal combinations of testing methods to make TB diagnosis available where people first seek care.
The work targets the four million people with active TB who go undiagnosed and untreated each year, including more than half of all children with TB, by improving access to TB screening and diagnosis.

**Vaccine Equity Cooperative [nee Initiative]** [to 010 Sep 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 010 Sep 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

**Vaccine Confidence Project** [to 010 Sep 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 010 Sep 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

**Wellcome Trust** [to 010 Sep 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

**The Wistar Institute** [to 10 Sep 2022]
Press Releases
Sep. 8, 2022
**The Wistar Institute Welcomes Michele A. Schiavoni, New Vice President of Communications & Marketing**
Wistar is pleased to announce the appointment of Michele A. Schiavoni, M.S., as Vice President of Communications & Marketing.

Press Release
Sep. 7, 2022
**The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils Halts Cancer Progression and Metastasis**
Novel PAD4 inhibitor reduces primary tumor, metastases and enhances checkpoint inhibitor treatments.

WFPHA: World Federation of Public Health Associations [to 010 Sep 2022]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

World Bank [to 010 Sep 2022]
Selected News, Announcements
New Fund for Pandemic Prevention, Preparedness and Response Formally Established
Designed to reflect inclusive and effective governance and operating arrangements with high standards of transparency and accountability; hosted by the World Bank with technical leadership from WHO
WASHINGTON...
Date: September 09, 2022 Type: Press Release

Remarks by President David Malpass at the Inaugural Governing Board Meeting of the Financial Intermediary Fund (FIF) for Pandemic Prevention, Preparedness and Response (PPR)
Good morning to colleagues joining us from around the world. I am very pleased to welcome you to this Inaugural Governing Board Meeting of the new Financial Intermediary Fund (FIF) for Pandemic Prevention...
Date: September 08, 2022 Type: Statement

World Customs Organization – WCO [to 010 Sep 2022]
http://www.wcoomd.org/
Latest News
08 September 2022
WCO and WHO cooperation enhanced through the signing of a new cooperation agreement

World Organisation for Animal Health (OIE) [to 010 Sep 2022]
https://www.oie.int/en/
Press Releases, Statements
No new digest content identified.

WTO - World Trade Organisation [to 010 Sep 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
No new digest content identified.

::::::

ARM [Alliance for Regenerative Medicine] [to 010 Sep 2022]
Selected Press Releases
No new digest content identified.

**BIO** [to 010 Sep 2022]
Press Releases
No new digest content identified.

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 010 Sep 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

**ICBA – International Council of Biotechnology Associations** [to 010 Sep 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

**IFPMA** [to 010 Sep 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
IFPMA statement at the 75th session of the WHO Regional Committee for South-East Asia
07 September 2022

**International Alliance of Patients’ Organizations – IAPO** [to 010 Sep 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

**International Generic and Biosimilar Medicines Association [IGBA]**
https://www.igbamedicines.org/
News
No new digest content identified.

**PhRMA** [to 010 Sep 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

::::::
Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases
Sep 06: Bharat Biotech’s iNCOVACC world’s first Intra Nasal vaccine receives approval for emergency use in India

BioCubaFarma – Cuba
Últimas Noticias - No new digest announcements identified

Biological E
News - No new digest announcements identified

BioNTech
Press Releases
BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines
07 Sep 2022

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News
Sep 6, 2022
Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia below.

GSK
Press releases for media
06 September 2022
WHO grants prequalification to GSK’s Mosquirix – the first and only approved malaria vaccine

**IMBCAMS, China**
*Home* - Website not responding at inquiry

**Janssen/JNJ**
*Press Releases* - No new digest announcements identified

**Medicago**
*Media* - No new digest announcements identified

**Merck**
*News releases* - No new digest announcements identified

**Moderna**
*Press Releases* - No new digest announcements identified

**Nanogen**
*News* - No new digest announcements identified

**Novartis**
*News* - No new digest announcements identified

**Novavax**
*Press Releases* - No new digest announcements identified

**Pfizer**
*Recent Press Releases*
09.07.2022  *Press Releases*
**FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women**

**R-Pharm**
https://rpharm-us.com/index.php
[No news or media page identified]

**Sanofi Pasteur**
*Press Releases* - No new digest announcements identified

**Serum Institute of India**
*NEWS & ANNOUNCEMENTS* - No new digest announcements identified

**Shifa Pharmed** [Iran]
http://shafapharmed.com/
No news page identified.

**Sinopharm/WIBP/BIBP**
News - No new digest announcements identified

Sinovac
Press Releases
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
2022/09/06

SK Biosciences
Press Releases - No new digest announcements identified

Valneva
Press Releases
September 8, 2022
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

September 6, 2022
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

Vector State Research Centre of Viralogy and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

* * * * *

* * * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022  Issue 3
AMA Journal of Ethics
Volume 24, Number 9: E817-912   Sep 2022

What We Owe Workers in Health Care Earning Low Wages
If you’re a professional caregiver in the US with colleagues paid a minimum wage, their labor is valued so little that it would be a crime to pay them less. The US Federal Fair Labor Standards Act of 1938 requires employers under its jurisdiction to pay workers at least a federal minimum wage. Yet in most of the US, a living wage is at least twice that amount. Privation, risk of injury and illness, uninsurance, and underinsurance undermine equity for health aides, environmental services workers, nursing and medical assistants, paramedics, and their children in the US. This theme issue investigates what we—as citizens, clinicians of status, and organizations—owe these vulnerable workers, on whose hour-to-hour care of some of our most vulnerable patients we heavily rely and woefully undervalue.

American Journal of Infection Control
September 2022  Volume 50  Issue 9  p969-1076
http://www.ajicjournal.org/current

Major Articles
A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital
Se Yoon Park, Tae Hyong Kim, Eunjung Lee,...Hyein Park, SoYea Jo, Ji Woo Sim
Published online: May 20, 2022
p1006-1012

American Journal of Preventive Medicine
September 2022  Volume 63  Issue 3  p313-468
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
September 2022  112(9)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 3_Suppl (Sep 2022)
https://www.ajtmh.org/view/journals/tpmd/107/3_Suppl/tpmd.107.issue-3_Suppl.xml

Malaria Transmission Blocking Vaccines
Editorial
Open access
Transmission-Blocking Vaccines: From Conceptualization to Realization
Louis H. Miller, Patrick E. Duffy, and Richard Culleton
A false sense of security
Piero A. Bonatti
Article 103741
Abstract
The growing literature on confidentiality in knowledge representation and reasoning sometimes may cause a false sense of security, due to lack of details about the attacker, and some misconceptions about security-related concepts. This note analyzes the vulnerabilities of some recent knowledge protection methods to increase the awareness about their actual effectiveness and their mutual differences.
Measuring inequalities in COVID-19 vaccination uptake and intent: results from the Canadian Community Health Survey 2021

By July 2021, Canada had received enough COVID-19 vaccines to fully vaccinate every eligible Canadian. However, despite the availability of vaccines, some eligible individuals remain unvaccinated. Differences...

Authors: Mireille Guay, Aubrey Maquiling, Ruoke Chen, Valérie Lavergne, Donalyne-Joy Baysac, Audrey Racine, Eve Dubé, Shannon E. MacDonald and Nicolas L. Gilbert

Citation: BMC Public Health 2022 22:1708
Content type: Research Published on: 8 September 2022

An overview of implementing an evidence based program to increase HPV vaccination in HIV community clinics

HPV-related anal cancer occurs in excess rates among people living with HIV (PLWH) and has been increasing in incidence. The HPV vaccine is an effective and safe approach to prevent and reduce the risk of HPV...

Authors: Jessica Wells, James L. Klosky, Yuan Liu and Theresa Wicklin Gillespie

Citation: BMC Public Health 2022 22:1696

Polio is a disease caused by poliovirus which can in turn cause irreversible paralytic disease, presenting as Acute Flaccid Paralysis (AFP). A sensitive AFP surveillance system, in which all reported AFP cases are...  
Authors: Bob Omoda Amodan, Annet Kisakye, Patricia Thiwe Okumu, Sherry Rita Ahirirwe, Daniel Kadobera, Alfred Driwale and Alex Riolexus Ario  
Citation: BMC Public Health 2022 22:1694  
Content type: Research Published on: 7 September 2022

**COVID-19 related stigma among the general population in Iran**

COVID-19 related stigma has been identified as a critical issue since the beginning of the pandemic. We developed a valid and reliable questionnaire to measure COVID-19 related enacted stigma, inflicted by the...  
Citation: BMC Public Health 2022 22:1681  
Content type: Research Published on: 7 September 2022

**BMC Research Notes**

http://www.biomedcentral.com/bmcresearchnotes/content  
(Accessed 010 Sep 2022)

**Assessing the impact of non-pharmaceutical interventions (NPIs) and BCG vaccine cross-protection in the transmission dynamics of SARS-CoV-2 in eastern Africa**

The outbreak of the novel coronavirus disease 2019 (COVID-19) is still affecting African countries. The pandemic presents challenges on how to measure governmental, and community responses to the crisis. Beyon...  
Authors: Chelsea Mbeke Kilonzo, Mark Wamalwa, Solange Youdom Whegang and Henri E. Z. Tonnang  
Citation: BMC Research Notes 2022 15:283  
Content type: Research note Published on: 4 September 2022

**BMJ Evidence-Based Medicine**

August 2022 - Volume 27 - 4  
https://ebm.bmj.com/content/27/4  
[Reviewed earlier]

**BMJ Open**

September 2022 - Volume 12 - 9  
https://bmjopen.bmj.com/content/12/9
Original research: Pre-emptive oral cholera vaccine (OCV) mass vaccination campaign in Cuamba District, Niassa Province, Mozambique: feasibility, vaccination coverage and delivery costs using CholTool (7 September, 2022)
Jucunú J Elias Chitio, Cynthia S Baltazar, José Paulo Langa, Liliana Dengo Baloi, Ramos B J Mboane, José Alberto Manuel, Sadate Assane, Alide Omar, Mariana Manso, Igor Capitine, Craig Van Rensburg, Naira Luiz, Vittal Mogasale, Florian Marks, Se Eun Park, Namseon S Beck

Original research: Attitudes towards coronavirus (COVID-19) vaccine and sources of information across diverse ethnic groups in the UK: a qualitative study from June to October 2020 (1 September, 2022)

Bulletin of the World Health Organization
Volume 100(9); 2022 Sep 1
https://www.ncbi.nlm.nih.gov/pmc/issues/415561/

Editorials
Planning for future COVID-19 vaccine procurement
Yot Teerawattananon, Siobhan Botwright, Murat Hakan Ozturk
Bull World Health Organ. 2022 Sep 1; 100(9): 526–526A. Published online 2022 Sep 1. doi: 10.2471/BLT.22.288729
PMCID: PMC9421551

Systematic Reviews
Infodemics and health misinformation: a systematic review of reviews
Israel Júnior Borges do Nascimento, Ana Beatriz Pizarro, Jussara M Almeida, Natasha Azzopardi-Muscat, Marcos André Gonçalves, Maria Björklund, David Novillo-Ortiz
Bull World Health Organ. 2022 Sep 1; 100(9): 544–561. Published online 2022 Jun 30. doi: 10.2471/BLT.21.287654
PMCID: PMC9421549

Perspectives
Psychosocial training and support guidelines for research staff
Raquel Burgess, Andrew Wooyoung Kim, Lindile Cele, Seema Khadka, Kripa Sigdel, Ashley K Hagaman
Bull World Health Organ. 2022 Sep 1; 100(9): 578–580. Published online 2022 Jul 13. doi: 10.2471/BLT.21.287159
PMCID: PMC9421552

Cell
Sep 01, 2022 Volume 185 Issue 18 p3279-3458
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
COVID-19 vaccination in the Gaza Strip: a cross-sectional study of vaccine coverage, hesitancy, and associated risk factors among community members and healthcare workers

The Gaza Strip, like other settings of complex humanitarian emergencies, faces immense challenges in vaccinating its population against COVID-19. This study was conducted in October 2021 among Gaza’s adult pop...

Authors: Jennifer Majer, Jehad H. Elhissi, Nabil Mousa and Natalya Kostandova
Citation: Conflict and Health 2022 16:48
Content type: Research Published on: 9 September 2022
Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
August 2022 - Volume 35 - Issue 4
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 3  Pages: 123-180  September 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 6, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 4 - August 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 46, Issue 3  Pages: 587-852  July 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23 Issue 9  5 September 2022
https://www.embopress.org/toc/14693178/current
Editorial  5 August 2022 Free Access
Publishing unpredictable research outcomes
Esther Schnapp, Bernd Pulverer

EMBO Reports welcomes ‘Independent First Confirmation’ studies for important findings. The editors will also consider well-developed null data on pivotal open questions in the biosciences, and studies that refute prominent published claims.

Emerging Infectious Diseases
Volume 28, Number 7—July 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 39  June 2022
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 5  Pages: 1-21  September–October 2022
https://onlinelibrary.wiley.com/toc/25782363/current

Protecting healthy volunteers • IRBs and research biopsies
Articles  Open Access

Ethical Criteria for Improved Human Subject Protections in Phase I Healthy Volunteer Trials
Rebecca L. Walker, Douglas MacKay, Margaret Waltz, Anne D. Lyerly, Jill A. Fisher
Pages: 2-21
First Published: September–October 2022

Broad Consent—Are We Asking Enough?
Lisa E. Smilan
Pages: 22-31
First Published: September–October 2022

Case Study
Informed Consent for Placebo-Controlled Trials: Do Ethics and Science Conflict?
Hope A. Feldman, James A. Feldman, Charles C. Miller, Garrett Walsh, Jon E. Tyson
Pages: 42-48
First Published: September–October 2022

Ethics & International Affairs
Ethics, Medicine and Public Health
Volume 23   August 2022
[Reviewed earlier]

The European Journal of Public Health
Volume 32, Issue 4, August 2022
https://academic.oup.com/eurpub/issue/32/4
Health services research

**Health care patterns and policies in 18 European countries during the first wave of the COVID-19 pandemic: an observational study**
Dimitra Panteli, Christoph Reichebner, Tanja Rombey, Elke Berger, Juliane Winkelmann ...
European Journal of Public Health, Volume 32, Issue 4, August 2022, Pages 557–564,
https://doi.org/10.1093/eurpub/ckac059

**Vaccination**
Editor's Choice

**The politics of vaccine hesitancy in Europe**
Florian Stoeckel, Charlie Carter, Benjamin A Lyons, Jason Reifler
European Journal of Public Health, Volume 32, Issue 4, August 2022, Pages 636–642,
https://doi.org/10.1093/eurpub/ckac041

**COVID 19**

**Impact of the COVID-19 pandemic on contact tracing of patients with pulmonary tuberculosis**
Pere Godoy, Ignasi Parrón, Irene Barrabeig, Joan A Caylà, Laura Clotet ...
European Journal of Public Health, Volume 32, Issue 4, August 2022, Pages 643–647,
https://doi.org/10.1093/eurpub/ckac031

**The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis**
Vageesh Jain, Paula Lorgelly
European Journal of Public Health, Volume 32, Issue 4, August 2022, Pages 648–654,
https://doi.org/10.1093/eurpub/ckac039

**Higher risk, higher protection: COVID-19 risk among immigrants in France—results from the population-based EpiCov survey**
Anne Gosselin, Josiane Warszawski, Nathalie Bajos, for the EpiCov Study Group
European Journal of Public Health, Volume 32, Issue 4, August 2022, Pages 655–663,
https://doi.org/10.1093/eurpub/ckac046
Expert Review of Vaccines
Vol 21 (8) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 3 July/August 2022
https://www.foreignaffairs.com/issues/2022/101/4
[Reviewed earlier]

Foreign Policy
Spring 2022
https://foreignpolicy.com/the-magazine/?issue_id=411130839
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
Research article  Abstract only
Challenges for precision public health communication in the era of genomic medicine
Aviad Raz, Stefan Timmermans, Gil Eyal, Kyle Brothers, Jusaku Minari
Pages 1814-1820

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 010 Sep 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
August 2022 | Volume 10 | Number 4
http://www.ghspjournal.org/content/current
Public health research priorities for WHO on COVID-19 in the South-East Asia Region: results of a prioritization survey

Effectively addressing the coronavirus disease 2019 (COVID-19) pandemic caused by the new pathogen requires continuous generation of evidence to inform decision-making. Despite an unprecedented amount of resea...
International Human Rights Law Review
Volume 11 (2022): Issue 1 (Jun 2022)
https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml
Table of Contents
Human Rights Implications of Stroke Biobanking and Genomics Research in Sub-Saharan Africa
Authors: Muyiwa Adigun, Babatunde Raphael Ojebuyi, Joshua Akinyemi, Kolawole Wahab, Albert Akpalu, Fred S. Sarfo, Lukman F. Owolabi, Rabiu Musbahu, Abiodun Bello, Reginald Obiako, Mayowa Ogunronbi, Arti Singh, Michelle Nichols, Carolyn Jenkins, Ayodele Jegede, Rajesh Kalaria, Mayowa Owolabi, Bruce Ovbiagele, Oyedunni Arulogun, and Rufus Akinyemi
Pages: 112–137
Online Publication Date: 27 Jun 2022

International Journal of Community Medicine and Public Health
Vol 9, No 9 (2022) September 2022
https://www.ijcmph.com/index.php/ijcmph/issue/view/92
Original Research Articles
Willingness to receive COVID-19 vaccine booster among general population of India: an online cross sectional study
Priyanka , Manasi Panda, Jugal Kishore
DOI: https://dx.doi.org/10.18203/2394-6040.ijcmph20222224
Published: 2022-08-26

International Journal of Epidemiology
Volume 51, Issue 4, August 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 15 Issue 2, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/2
Table of Contents
[Reviewed earlier]

JAMA
September 6, 2022, Vol 328, No. 9, Pages 799-898
https://jamanetwork.com/journals/jama/currentissue
Research Letter
Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection
Young-Eun Kim, PhD; Kyungmin Huh, MD; Young-Joon Park, MD, MPH; et al.
free access has active quiz
This retrospective cohort study examines the incidence of acute myocardial infarction and ischemic stroke after COVID-19 infection among vaccinated vs unvaccinated adults in Korea.

**Viewpoint**  
**Addressing the Long-term Effects of COVID-19**  
Rachel L. Levine, MD  
has multimedia has audio  
JAMA. 2022;328(9):823-824. doi:10.1001/jama.2022.14089  
This Viewpoint from US Assistant Secretary for Health Rachel Levine summarizes current understanding of “Long COVID” and addresses the need for agreed-upon terminology, further research and diagnostics, and an effective approach for addressing the long-term effects of COVID-19.  
**Audio Author Interview: Long COVID: The US Federal Response**

**JAMA Pediatrics**  
September 2022, Vol 176, No. 9, Pages 837-952  
https://jamanetwork.com/journals/jamapediatrics/currentissue  
[New issue; No digest content identified]

**JBI Evidence Synthesis**  
August 2022 - Volume 20 - Issue 8  
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx  
[Reviewed earlier]

**Journal of Adolescent Health**  
September 2022 Volume 71 Issue 3 p251-380  
https://www.jahonline.org/current  
[New issue; No digest content identified]

**Journal of Artificial Intelligence Research**  
Vol. 74 (2022)  
https://www.jair.org/index.php/jair  
[Reviewed earlier]

**Journal of Community Health**  
Volume 47, issue 4, August 2022  
https://link.springer.com/journal/10900/volumes-and-issues/47-4  
[Reviewed earlier]

**Journal of Development Economics**  
Volume 158 September 2022  
[Reviewed earlier]
Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 4, October 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
September 2022 - Volume 76 - 9
https://jech.bmj.com/content/76/9
[New issue; No digest content identified]

Journal of Evidence-Based Medicine
Volume 15, Issue 2 Pages: 73-179 June 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current
*Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications*
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 3, August 2022
https://muse.jhu.edu/issue/48370
*Table of Contents*
*Brief Communications*
**Racial Disparities in Nursing Home Resident and Staff COVID-19 Vaccination Rates**
Danya M. Qato, Sean P. Fleming, Alexandra Wallem, Linda Wastila
pp. 1129-1134
DOI: 10.1353/hpu.2022.0099

**Associations of Incomplete SARS-CoV-2 Vaccination among Patients with Unstable Housing in Houston**
J. Thomas Gebert, Evan Shegog, Emily Xiao, James Fan, Mary McEvoy, Audrey Lopez, Dana Clark
pp. 1146-1154
DOI: 10.1353/hpu.2022.0101

*Original Papers*
**Patient Income Does Not Predict Disability or Mortality in Hospitalized COVID-19 Patients in a Large Health Care System in the Chicago Metropolitan Area**
Brian Stamm, Regina Royan, Jeffrey R. Clark, Steven C. Hoffman, Nathan A. Shlobin, Zachary S. Orban, Patrick H. Lim, Igor J. Koralnik, Eric M. Liotta, Ayush Batra
pp. 1215-1229
DOI: 10.1353/hpu.2022.0108

**Flattening Epidemic Curves and COVID-19: Policy Rationales, Inequality, and Racism**
William P. Brandon
pp. 1700-1714
DOI: 10.1353/hpu.2022.0095

**Literature Review**

**Assessing Black America's Experience During the COVID-19 Plague**
William P. Brandon
pp. 1715-1718
DOI: 10.1353/hpu.2022.0096

**Journal of Immigrant and Minority Health**
Volume 24, issue 5, October 2022

**Contents**
[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**
Volume 20, 2022 , Issue 3
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

**Journal of Infectious Diseases**
Volume 225, Issue 12, 15 June 2022
https://academic.oup.com/jid/issue/225/12
[Reviewed earlier]

**Journal of International Development**
Volume 34, Issue 6 Pages: 1069-1255 August 2022
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

**Journal of Medical Ethics**
August 2022 - Volume 48 - 8
http://jme.bmj.com/content/current
[Reviewed earlier]
The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
A.N. M. Kraay, et al.
Published:07 September 2022Article ID:20220477

Abstract
Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution...
might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts.
Lancet Global Health
Sep 2022 Volume 10 Number 9 e1209-e1359
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Sep 2022 Volume 22 Number 9 p1253-1398, e239-e278
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Sep 2022 Volume 7 Number 9 e725-e800
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Sep 2022 Volume 10 Number 9 p811-924, e78-e86
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 26, issue 9, September 2022
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 42 Issue 6, August 2022
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 100, Issue 2 Pages: 315-616 June 2022
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Nature
Volume 609 Issue 7926, 8 September 2022
https://www.nature.com/nature/volumes/609/issues/7926
Editorial 06 Sept 2022
Liz Truss must value science, not fear it
Populist slogans won’t cut it: the new UK government has nothing to lose and everything to gain by working constructively with scientists and universities.

Editorial   07 Sept 2022

Zero tolerance for threats against scientists
Too often, researchers who share their expertise on contentious topics such as COVID-19 are subjected to abuse. Their institutions must step in to defend and protect them.

Comment   05 Sept 2022

Scientists in Ukraine have long fought for scientific freedom
Researchers in the country have often shown creativity and resilience under threat. These strengths will be key to the future of science in Ukraine following Russia’s invasion.
James Poskett, Claire Shaw

Nature Biotechnology
Volume 40 Issue 9, September 2022
https://www.nature.com/nbt/volumes/40/issues/9
Editorial   30 Aug 2022
One pangenome to bind them all
The pangenome provides a first glimpse of the scope of human genetic diversity. But its routine adoption into research and clinical practice faces several challenges.

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 010 Sep 2022)
[No new digest content identified]

Nature Genetics
Volume 54 Issue 8, August 2022
https://www.nature.com/ng/volumes/54/issues/8
[Reviewed earlier]

Nature Human Behaviour
Volume 6 Issue 8, August 2022
https://www.nature.com/nathumbehav/volumes/6/issues/8
[Reviewed earlier]

Nature Medicine
Volume 28 Issue 8, August 2022
https://www.nature.com/nm/volumes/28/issues/8
[Reviewed earlier]
Nature Reviews Drug Discovery
Volume 21 Issue 9, September 2022
https://www.nature.com/nrd/volumes/21/issues/9
[Reviewed earlier]

Nature Reviews Genetics
Volume 23 Issue 9, September 2022
https://www.nature.com/nrg/volumes/23/issues/9
[Reviewed earlier]

Nature Reviews Immunology
Volume 22 Issue 9, September 2022
https://www.nature.com/nri/volumes/22/issues/9
[Reviewed earlier]

New England Journal of Medicine
September 8, 2022  Vol. 387 No. 10
https://www.nejm.org/toc/nejm/medical-journal
Perspective
Science, Competing Values, and Trade-offs in Public Health — The Example of Covid-19 and Masking
S.C. Dupont and S. Galea

Editorials
Audio Interview: Rolling Out New Covid-19 Vaccines
E.J. Rubin, L.R. Baden, and S. Morrissey

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 010 Sep 2022]
[No new digest content identified]

Pediatrics
Volume 150, Issue 3  September 2022
https://publications.aap.org/pediatrics/issue/150/3
Articles
Impact of Routine Childhood Immunization in Reducing Vaccine-Preventable Diseases in the United States
Sandra E. Talbird, MSPH; Justin Carrico, BS; Elizabeth M. La, PhD; Cristina Carias, PhD; Gary S. Marshall, MD ...

Value of the Immunization Program for Children in the 2017 US Birth Cohort
Justin Carrico, BS; Elizabeth M. La, PhD; Sandra E. Talbird, MSPH; Ya-Ting Chen, PhD; Mawuli K. Nyaku, DrPh, MBA, MPH ...

**Medications and Adherence to Treatment Guidelines Among Children Hospitalized With Acute COVID-19**
Julianne E. Burns, MD, MSCE; Cary Thurm, PhD; James W. Antoon, MD, PhD; Carlos G. Grijalva, MD, MPH; Matt Hall, PhD ...

**Text Message Reminders for the Second Dose of Influenza Vaccine for Children: An RCT**
Melissa S. Stockwell, MD, MPH; Laura P. Shone, DrPH; Ekaterina Nekrasova, MPH; Chelsea Wynn, MPH; Alessandra Torres, MPH

**Commentaries**
**Vaccines Are Profoundly Effective, and We Can’t Stop There**
Michael D. Warren, MD, MPH; Monique Fountain Hanna, MD, MPH, MBA

**Policy Statement:**
**COVID-19 Vaccines in Infants, Children, and Adolescents**
COMMITTEE ON INFECTIOUS DISEASES

**PharmacoEconomics**
Volume 40, issue 9, September 2022
[Reviewed earlier]

**PLoS Biology**
https://journals.plos.org/plosbiology/
(Accessed 010 Sep 2022)
[No new digest content identified]

**PLoS Genetics**
https://journals.plos.org/plosgenetics/
(Accessed 010 Sep 2022)
[No new digest content identified]

**PLoS Medicine**
http://www.plosmedicine.org/
(Accessed 010 Sep 2022)
*Editorial*
**Time to end parachute science**
Beryne Odeny, Raffaella Bosurgi
| published 06 Sep 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004099
Colonial science, also known as parachute or parasitic science, is an extractive practice whereby foreign researchers—typically from highly resourced countries—do research and extract data and samples from non-native regions or populations, typically low resource settings or countries, without appropriately acknowledging the importance of the local infrastructure and expertise that local scientists can bring to research. In so doing, foreign researchers fail to establish long term, equitable collaborations with local partners.

The era in which we are living is profoundly impacted by the effects of globalization, inequity, poverty, conflicts, climate change, biodiversity loss, and pandemics. Many of the solutions to these global health challenges come from sustainable and socially responsible behavior from societies; often, robust scientific evidence comes from collaborations among key opinion leaders, scientists, funders, policy makers, and local and international stakeholders across different countries. For research to be sustainable and equitable, it should be founded on inclusive scientific liaison between varied collaborators—for example, between high income countries (HICs) and low- and middle-income countries (LMICs), and early-career researchers and established scientists. Unfortunately, inclusivity and equity are not the reality in most global research...

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 010 Sep 2022)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 010 Sep 2022]
Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System
Laura Semenzato, Jérémie Botton, Bérangère Baricault, Jacqueline Deloumeaux, Clarisse Joachim, Emmanuelle Sylvestre, Rosemary Dray-Spira, Alain Weill, Mahmoud Zureik
Research Article | published 09 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274309

COVID-19 vaccine for people who live and work in prisons worldwide: A scoping review
Nasrul Ismail, Lara Tavoschi, Babak Moazen, Alicia Roselló, Emma Plugge
Research Article | published 09 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267070

Does perceived scarcity of COVID-19 vaccines increase vaccination willingness? Results of an experimental study with German respondents in times of a national vaccine shortage
Julia Schnepf
Research Article | published 07 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0273441

PLoS Pathogens
http://journals.plos.org/plospathogens/
Impactful scientists have higher tendency to involve collaborators in new topics

In scientific research, collaboration is one of the most effective ways to take advantage of new ideas, skills, and resources and for performing interdisciplinary research. Although collaboration networks have been intensively studied, the question of how ...

An Zeng, Ying Fan, [...] Shlomo Havlin

Prehospital & Disaster Medicine
Volume 37 - Issue 4 - August 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 162 September 2022
[Reviewed earlier]

Proceedings of the Royal Society B
14 September 2022 Volume 289 Issue 1982
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 210 Pages 1-162 (September 2022)
Review article Full text access
Behavioural determinants of COVID-19 vaccination acceptance among healthcare workers: a rapid review
J. Crawshaw, K. Konnyu, G. Castillo, Z. van Allen, ... J. Presseau

Research article Open access
Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group
N. Kirson, E. Swallow, J. Lu, C. Foroughi, ... P. Lefebvre
Pages 99-106

Research article Full text access
**Vaccination, life expectancy, and trust: patterns of COVID-19 and measles vaccination rates around the world**
C. Rughiniş, S.-N. Vulpe, M.G. Flaherty, S. Vasile
Pages 114-122

Special Section: Public Health Emergencies
Research article  Full text access

**Unwillingness to cooperate with COVID-19 contact tracing in Japan**
M. Machida, H. Kikuchi, T. Kojima, I. Nakamura, ... S. Inoue
Pages 34-40

**Abstract**
Objectives
Contact tracing for COVID-19 relies heavily on the cooperation of individuals with authorities to provide information of contact persons. However, few studies have clarified willingness to cooperate and motivation to provide information for contact tracing. This study sought to describe willingness to cooperate and motivation to report contact persons for COVID-19 contact tracing among citizens in Japan, and to assess any associated sociodemographic factors.

Study design
Cross-sectional study.

Methods
This was an online-based survey using quota sampling. Participants were asked about their willingness to cooperate in reporting contacts for COVID-19 contact tracing if they tested positive. Participants also responded to questions regarding their reasons for cooperating or not cooperating and provided sociodemographic data. Multiple logistic regression analysis was performed to clarify associations between sociodemographic factors and willingness to cooperate.

Results
This study included 2844 participants. The proportion of participants who were not willing to cooperate in reporting contacts was 27.6%, with their main reasons being concerns about causing trouble for the other person and being criticised for revealing their names. Willingness to cooperate was lower among men, young adults and those with an educational level less than a university degree.

Conclusions
To improve the effectiveness of contact tracing, educational campaigns, such as reducing the fear and stigma associated with COVID-19, may be important. Furthermore, it is essential to understand that individuals may have contacts whom they do not wish to disclose to others and to be considerate when handling such situations.

**Public Health Ethics**
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

**Public Health Reports**
Volume 137 Issue 4, July/August 2022
https://journals.sagepub.com/toc/phrg/137/4
[Reviewed earlier]
Qualitative Health Research
Volume 32 Issue 11, September 2022
http://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 18 Issue 3, July 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 010 Sep 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health
(RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
3 Sep 2022
Integrated approach for noncommunicable disease management in the Americas
Current topic | English |

Risk Analysis
Volume 42, Issue 8 Pages: 1603-1890 August 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Machine Learning and Other Information Analyses for Risk in Social Networks
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 010 Sep 2022]
Original Research
Factors Associated with the Acceptance of COVID-19 Vaccines in Citizens of Northern Peru: Cross-Sectional Study
Yupari-Azabache IL, Díaz-Ortega JL, Bardales-Aguirre LB, Barros-Sevillano S, Paredes-Díaz SE
Risk Management and Healthcare Policy 2022, 15:1705-1715
Published Date: 9 September 2022
Review
Building the Culture of Public Health as a Positive Reflection from the COVID-19 Crisis
Alsaqqa HH
Protect the vulnerable from monkeypox

BY Boghuma Titanji
08 Sep 2022: 1129

Policy Forum

Exclusion cycles: Reinforcing disparities in medicine
BY Ana Bracic, Shawneequa L. Callier, W. Nicholson Price II
08 Sep 2022: 1158-1160

Clinical practice, data collection, and medical AI constitute self-reinforcing and interacting cycles of exclusion.
The never-ending global emergence of viral zoonoses after COVID-19? The rising concern of monkeypox in Europe, North America and beyond
Darwin A. León-Figueroa, D. Katterine Bonilla-Aldana, Monica Pachar, Luccio Romaní, ... Alfonso J. Rodriguez-Morales
Article 102362

The emergence of cholera in multiple countries amidst current COVID-19 pandemic: Situation and implications for public health and travel medicine
Abduallah Reda, Ranjit Sah, Abdelaziz Abdelaal, Sunil Shrestha, Alfonso J. Rodriguez-Morales
Article 102423

Acceptance towards COVID-19 vaccination in Latin America and the Caribbean: A systematic review and meta-analysis
Esteban A. Alarcón-Braga, Enrique A. Hernandez-Bustamante, Farley E. Salazar-Valdivia, Valeria A. Valdez-Cornejo, ... Jessica H. Zafra-Tanaka
Article 102369

New challenges in human monkeypox outside Africa: A review and case report from Italy
Davide Mileto, Agostino Riva, Miriam Cutrera, Davide Moschese, ... Spinello Antinori
Article 102386

Monkeypox caused less worry than COVID-19 among the general population during the first month of the WHO Monkeypox alert: Experience from Saudi Arabia
Mohamad-Hani Temsah, Fadi Aljamaan, Shuliweeh Alenezi, Khalid Alhasan, ... Jaffar A. Al-Tawfiq
Article 102426

Monkeypox outbreak: Preventing another episode of stigmatisation
Chee Tao Chang, Chern Choong Thum, Xin Jie Lim, Chii Chii Chew, Philip Rajan
Pages: 754-757
First Published: 02 July 2022
**Crowdfunding narratives and the valuation of vaccines for COVID-19**
Jeremy Snyder, Maya J. Goldenberg, Valorie A. Crooks, Rachel Katz
Pages 5295-5298

**COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries**
Vyankatesh Pidiyar, Ganesh Kumraj, Kafil Ahmed, Syed Ahmed, ... Sushmita Mukherjee
Pages 5302-5312

**Adult vaccination uptake strategies in low- and middle-income countries: A systematic review**
Janamarie M. Perroud, Shad Soldano, Anton L.V. Avanceña, Abram Wagner
Pages 5313-5321

**COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications**
Teck Chuan Voo, Julian Savulescu, Owen Schaefer, Abel Ho Zhi Ling, Clarence C. Tam
Pages 5333-5337

**Cost-effectiveness of rotavirus vaccination in Mozambique**
Esperança Lourenço Guimarães, Assucênio Chissaque, Clint Pecenka, Andrew Clark, ... Frédéric Debellut
Pages 5338-5346

**Assessing knowledge of human papillomavirus among men who have sex with men (MSM) using targeted dating applications**
Dalton Pham, Anubhuti Shukla, Kelly Welch, Alessandro Villa
Pages 5376-5383

**Should COVID-19 vaccines be mandated in schools? - an international caregiver perspective**
Shannon H. Baumer-Mouradian, Rebecca J. Hart, Jeffrey N. Bone, Michelle Seiler, ... Ran D. Goldman
Pages 5384-5390

**Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan**
Rozina S. Thobani, Mohammad Tahir Yousafzai, Shazia Sultana, Abdul Momin Kazi, ... Farah Naz Qamar
Value in Health
September 2022 Volume 25 Issue 9 p1463-1662
https://www.valueinhealthjournal.com/current

ECONOMIC EVALUATION
Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study
Nirma Khatri Vadlamudi, et al.
Published online: April 21, 2022

POLICY PERSPECTIVE
Should We Consider Including a Value for “Hope” as an Additional Benefit Within Health Technology Assessment?
Published online: April 28, 2022

-------
-------

Pre-Print Servers
Gates Open Research
https://gatesopenresearch.org/browse/articles
Selected Research
[No new digest content identified]

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...
Selected Research
The Most Cost-Efficient And Effective Set Of COVID-19 Policies To Reduce Monthly COVID-19 Case Increase Rates
Charline Chen
medRxiv 2022.09.04.22279016; doi: https://doi.org/10.1101/2022.09.04.22279016

Effectiveness of BNT162b2 and CoronaVac against paediatric COVID-19-associated hospitalization and moderate-to-severe disease
Jaime S Rosa Duque, Daniel Leung, Ka Man Yip, Derek H. L. Lee, Hung-kwan So, Wilfred H. S. Wong, Yu Lung Lau
medRxiv 2022.09.09.22279426; doi: https://doi.org/10.1101/2022.09.09.22279426
Modeling vaccine allocation and equity implications of COVID-19 containment strategies
Ichiro Nakamoto
medRxiv 2022.09.05.22279623; doi: https://doi.org/10.1101/2022.09.05.22279623

Psychological factors associated with reporting side effects following COVID-19 vaccination: a prospective cohort study (CoVAccS - wave 3)
Louise E. Smith, Julius Sim, Susan Mary Sherman, Richard Amlôt, Megan Cutts, Hannah Dasch, Nick Sevdalis, James Rubin
medRxiv 2022.09.07.22279682; doi: https://doi.org/10.1101/2022.09.07.22279682

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratnadawan Aemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thanunrat Thongmee, Apirat Katanyutanon, Wichai Thanasopon, Jirawan Arayapong, Withak Withaksabut, Donchida Srimuan, Thaksaporn Thatsanatorn, Natthinee Sudhinaratset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan
medRxiv 2022.09.07.22279684; doi: https://doi.org/10.1101/2022.09.07.22279684

Containing monkeypox on a college campus: a model-based analysis
Alexandra Savinkina, Melanie H Chitwood, Jiye Kwon, Virginia E. Pitzer, Gregg S. Gonsalves, A David Paltiel
medRxiv 2022.09.06.22279540; doi: https://doi.org/10.1101/2022.09.06.22279540

Global biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts
medRxiv 2021.11.18.21266545; doi: https://doi.org/10.1101/2021.11.18.21266545 Revision

Community engagement to increase vaccine uptake: Quasi-experimental evidence from Islamabad and Rawalpindi, Pakistan
Mujahid Abdullah, Taimoor Ahmad, Twangar Kazmi, Faisal Sultan, Sabeen Afzal, Rana Muhammad Safdar, Adnan Ahmad Khan
medRxiv 2022.09.04.22279583; doi: https://doi.org/10.1101/2022.09.04.22279583

How Have Global Scientists Responded to Tackling COVID-19?
Longbing Cao, Wenfeng Hou
medRxiv 2022.08.16.22278871; doi: https://doi.org/10.1101/2022.08.16.22278871 Revision

Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers
Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Oscar Bladh, Wanda Christ, Max Gordon, Henry Ng, Kim Blom, Mia Phillipson, Sara Mangsbo, Anna Smed Sörensen, Peter Nilsson, Sophia Hober, Mikael Åberg, Jonas Klingström, Charlotte Thålin
Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants
Nawal Al Kaabi, Yun Kai Yang, Yu Liang, Ke Xu, Xue Feng Zhang, Yun Kang, Yu Qin Jin, Jun Wei Hou, Jing Zhang, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Ze Hua Lei, Hao Zhang, Shuai Shao, Zhao Ming Liu, Ning Liu, Xiang Zheng, Ji Guo Su, Sen Sen Yang, Xiangfeng Cong, Yao Tan, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Yang Liu, Jing Zhang, Mengjie Yang, Islam Eltantawy, Peng Xiao, Fu Jie Shen, Jin Juan Wu, Zi Bo Han, Li Fang Du, Fang Tang, Shi Chen, Zhi Jing Ma, Fan Zheng, Ya Nan Hou, Xin Yu Li, Xin Li, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li

The global distribution of COVID-19 vaccine: The role of macro-socioeconomics measures
Ali Roghani, Samin Panahi

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 010 Sep 2022]

Perceived Vulnerability to Infectious Disease and Perceived Harmfulness are as Influential as Partisanship in Shaping Citizen Response to COVID 19
Abigail Cassario

Correcting COVID-19 Vaccine Misinformation in Ten Countries
Ethan Porter
Thomas J. Wood
Yamil Velez

Cross-language Validation of COVID-19 Compliance Scale in 28 Languages
Angelique M. Blackburn
Hyemin Han
Objective: Although compliance scales have been used to assess compliance with health guidelines to reduce the spread of COVID-19, no scale known to us has shown content validity regarding global guidelines and reliability across a large international sample. Here, we have assessed the validity and...
comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers.

This living mapping review aims to supplement the database by providing an open accessible and frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analysis are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio.

Results: In this version seven analysis we provide an updated detailed descriptive analysis of the database (on data from three months after version six) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations and research locations (with a focus on resource-limited countries).

Conclusions: As the global funding response to COVID-19 plateaus, this living mapping review helps both funders and researchers to prioritise resources to areas where there is continued unmet research need.

* * * * *

**Think Tanks**

**Brookings** [to 10 Sep 2022]
http://www.brookings.edu/
Accessed 10 Sep 2022

*Latest Research [Selected]*

*Monetary Policy*

**Understanding US inflation during the COVID era**
Laurence Ball, Daniel Leigh, and Prachi Mishra
Wednesday, September 7, 2022

*Federal Fiscal Policy*

**Economic Impact Payments and household spending during the pandemic**
Jonathan A. Parker, Jake Schild, Laura Erhard, and David S Johnson
Wednesday, September 7, 2022

**Center for Global Development** [to 25 Jun 2022]
https://www.cgdev.org/

*All Research [Selected]*
[No new digest content identified]

**Chatham House** [to 010 Sep 2022]
https://www.chathamhouse.org/

*Selected Analysis, Comment*
[No new digest content identified]
CSIS  [to 010 Sep 2022]
https://www.csis.org/
Selected Reports/Content
[No new digest content identified]

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 010 Sep 2022
Publications
No new digest content identified.

ODI  [Overseas Development Institute]  [to 10 Sep 2022]
Publications
Advocating together to strengthen protection: collective efforts of international and national organisations
08 September 2022
Briefing/policy papers

Collaborative advocacy on the protection of civilians: children and armed conflict and explosive weapons in populated areas
08 September 2022
Research reports

Climate change, conflict and displacement: five key misconceptions
05 September 2022
Briefing/policy papers

Pew Research Center  [to 10 Sep 2022]
https://www.pewresearch.org/
Latest Publications
Short Read | Sep 6, 2022
Partisan differences are common in the lessons Americans take away from COVID-19
Here's what Americans said they learned about the development of vaccines and medical treatments and their advice for handling a future outbreak.

Rand  [to 10 Sep 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Journal Article
Use of Telehealth Across Pediatric Subspecialties Before and During the COVID-19 Pandemic
In this cohort study, 8 large pediatric medical groups in California collaborated to share aggregate data on telehealth use for 11 pediatric subspecialties from January 1, 2019, to December 31, 2021.
Report

Public Health and Soft Power: The Republic of Korea’s Initial COVID-19 Response and Its Implications for Health Diplomacy

The Republic of Korea's successful proactive response to the coronavirus 2019 pandemic has received global attention. How might the nation leverage this success to demonstrate soft power and help build a strong alliance for global health security?

Sep 7, 2022
Jennifer Bouey, Lynn Hu, Sohaela Amiri, Rafiq Dossani

Dissertation

Three Essays on HIV Investments in Sub-Saharan Africa

Examines the HIV-related health decisions and investments that are made by people living with HIV as well as the institutions that serve them, and it assesses their indirect effects.

Sep 6, 2022
Uzaib Saya

Urban Institute  [to 010 Sep 2022]
https://www.urban.org/publications

New Research Publications

World Economic Forum  [to 010 Sep 2022]
https://www.weforum.org/press/

Media

No new digest content identified

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

*: * * *
*: * *

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.
Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*  *  *  *  *
*  *  *  *  *